Philip Morris International Inc. (NYSE:PM) Q4 2022 Earnings Call Transcript

Page 9 of 9

So that will come with investment, but, of course, they are not of the same magnitude as the one that we’ve been making in order to be the capacity on IQOS, smaller volume, smaller base. So notwithstanding back on the long-term anyway.

Jared Dinges: Okay, that’s clear. And for the second one and maybe just on the Healthcare and Wellness segment, I mean, 2023 will be another investment year. I know you guys have talked about that that probably being a multiyear investment cycle. But I don’t know if you can give any indication on when you think that business could potentially start to contribute to growth and maybe also, could you guys talk about your learnings so far in those businesses that you have acquired?

Jacek Olczak: Yes I mean, look, they obviously, been very clear about this from the very beginning, I mean, in order to develop and bring to the market of a couple of the programs and products, which we have it in mind, I mean we have to go for the investments, we talked about us prefer also have a very promising investment in the medical of – in the medical space be cannabinoids et cetera. So all of this programs that they agree to establish milestones in terms of the – the development of these products including the series of clinicals and meeting of different regulatory expectation, so that’s about what’s going to be. We have said historically our ambitious target of achieving this $1 billion revenue by 2025, there is a pipeline of the product but the more interesting actually, what’s going to happen with that business beyond ’25, because it’s the longer-term, longer-term investment.

Obviously, when we allocate the capital, we look first with – we allocate the capital behind the — those things, which are in the near and mid-term for us and it’s obviously heat-not-burn and IQOS, ILUMA expansions to the US, and I can go through the long list of an opportunities but they’re keeping also denied. This businesses have a quite – wellness and healthcare offers us a very interesting opportunities in the longer run, when we very well leverage both our scientific life science expertise capabilities combined with the commercial et cetera. So, this is how I would look on this thing. I think when we meet on the – in September of this year for the Investors Day, we will start, obviously opening a much more longer-term horizon, how the management, how we see the future of PMI not just in the next year or two, but with the longer time of a perspective.

And this is the moment when, I guess, we will share more details, by the way, also I think we’ll be able to answer more precisely your first questions to Emmanuel, about the CapEx, because obviously, we open a 10 years horizon for Philip Morris, we will have to touch upon that capital allocation component as well.

Jared Dinges: Great, that’s helpful. Thank you.

Emmanuel Babeau: Thank you.

Jacek Olczak: Thank you.

Operator: It appears, we have no further questions at this time. I will now turn the program back over to management for any additional or closing remarks.

James Bushnell: Thank you. Before closing our call, I would like to remind you that we will be presenting at the CAGNY conference on February 22. And as we mentioned earlier, we plan to host the September Investor Day, in Switzerland. We hope, you will be able to join these events, either in person or virtually. That concludes our call today. Thank you again for joining us. If you have any follow-up questions, please contact the Investor Relations team. Thank you.

Jacek Olczak: Thank you. Talk to you soon.

Emmanuel Babeau: Thank you.

Operator: That concludes today’s teleconference. Thank you for your participation, you may now disconnect.

Follow Philip Morris International Inc. (NYSE:PM)

Page 9 of 9